Join Growin Stock Community!

Polypid ltd.PYPD.US Overview

US StockHealthcare
(No presentation for PYPD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PYPD AI Insights

PYPD Overall Performance

PYPD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PYPD Recent Performance

-

Polypid ltd.

0.05%

Avg of Sector

-0.31%

S&P500

PYPD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PYPD Key Information

PYPD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PYPD Profile

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Price of PYPD

PYPD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PYPD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.95
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
6.95
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PYPD's latest earnings report released?

    The most recent financial report for Polypid ltd. (PYPD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PYPD's short-term business performance and financial health. For the latest updates on PYPD's earnings releases, visit this page regularly.

  • How much debt does PYPD have?

    As of the end of the reporting period, Polypid ltd. (PYPD) had total debt of 2.8M, with a debt ratio of 0.13. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PYPD have?

    At the end of the period, Polypid ltd. (PYPD) held Total Cash and Cash Equivalents of 6.6M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PYPD's EPS continuing to grow?

    According to the past four quarterly reports, Polypid ltd. (PYPD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of PYPD?

    The latest valuation data shows Polypid ltd. (PYPD) has a Price-To-Earnings (PE) ratio of -2.29 and a Price/Earnings-To-Growth (PEG) ratio of -0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.